CytoMed Therapeutics (GDTC) Operating Leases (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Operating Leases for 5 consecutive years, with $41249.3 as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 138.27% to $41249.3 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41249.3 through Dec 2025, up 138.27% year-over-year, with the annual reading at $41575.0 for FY2025, 146.65% up from the prior year.
  • Operating Leases hit $41249.3 in Q4 2025 for CytoMed Therapeutics, up from $17311.9 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $41249.3 in Q4 2025 to a low of $4684.1 in Q4 2023.
  • Historically, Operating Leases has averaged $15873.5 across 5 years, with a median of $11287.7 in 2021.
  • Biggest five-year swings in Operating Leases: plummeted 57.17% in 2022 and later skyrocketed 269.59% in 2024.
  • Year by year, Operating Leases stood at $11287.7 in 2021, then tumbled by 57.17% to $4834.3 in 2022, then fell by 3.11% to $4684.1 in 2023, then surged by 269.59% to $17311.9 in 2024, then skyrocketed by 138.27% to $41249.3 in 2025.
  • Business Quant data shows Operating Leases for GDTC at $41249.3 in Q4 2025, $17311.9 in Q4 2024, and $4684.1 in Q4 2023.